|

IBI363 + chemotherapy Clinical Trials

3 actively recruiting trials

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • Zhejiang Cancer Hospital1
  • Shanghai Pulmonary Hospital, Shanghai, China1
  • Innovent Biologics (Suzhou) Co. Ltd.1

Indications

  • Cancer3
  • Unresectable Stage III Non-small Cell Lung Cancer1
  • IBI363 + Chemotherapy1
  • Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)1
  • Advanced Malignancies1

Other3 trials

A Study of IBI363 in Subjects With Advanced Malignancies
Phase 1
IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer
Phase 2
Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.